Table 2.
Covariate | Maximum between-group standardized differencebefore weighting (%) | Maximum between-group standardized differenceafter weighting (%) |
Age | 40.6 | 5.4 |
Male | 10.6 | 7.4 |
Race | ||
White | 13.8 | 5.2 |
Black | 15.6 | 5.7 |
Asian | 8.1 | 8.1 |
Pacific Islander | 4.1 | 2.4 |
Native American | 8.4 | 4.5 |
Family history of CAD | 11.1 | 2.5 |
Tobacco | 8.0 | 7.0 |
Hypertension | 11.6 | 3.4 |
Hyperlipidemia | 9.0 | 5.0 |
BMI | 13.2 | 2.2 |
Framingham risk score | 19.8 | 5.8 |
PAD | 15.7 | 5.9 |
CHF | 30.8 | 6.1 |
COPD | 6.2 | 2.5 |
CKD | 75.7 | 14.7 |
Dialysis | 26.1 | 14.0 |
Depression | 13.1 | 2.5 |
PTSD | 14.1 | 4.3 |
Presentation | ||
Stable angina | 6.9 | 7.5 |
Positive functional study | 15.7 | 4.2 |
Ischemic heart disease | 5.9 | 1.7 |
Chest pain | 13.8 | 2.0 |
Postangiography revascularization | ||
None | 10.7 | 4.6 |
PCI | 6.2 | 3.5 |
CABG | 8.0 | 4.2 |
Baseline HbA1c | 32.4 | 4.8 |
Diabetes duration | 16.6 | 5.3 |
BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HbA1c, hemoglobin A1c; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; PTSD, post-traumatic stress disorder.